Can vitamins and dietary micronutrients prevent or treat Alzheimer’s disease? It is a question concerning millions of people worldwide who are searching for ways to preserve their cognitive health in later life. Advertisements frequently promise miracles: multivitamins for memory impairment, antioxidants for neuroprotection, and specialist medical drinks targeting cognitive decline. Yet what does the scientific evidence actually show? The reality is sobering: most vitamin and mineral dementia supplements are ineffective against Alzheimer’s disease—and some, such as calcium supplementation, may even double dementia risk. In this evidence-based review, we examine 14 major clinical trials showing why Centrum Silver, vitamin E, beta-carotene, Souvenaid, and other popular products fail to deliver on their promises.
Alzheimer’s disease and antioxidant efficacy
Alzheimer’s disease is a progressive neurodegenerative condition that leads to worsening memory impairment and cognitive decline. As the most common form of dementia, it affects millions of people across the UK and worldwide. In the brains of Alzheimer’s patients, characteristic amyloid plaques and tau tangles accumulate, damaging nerve cells and ultimately causing neuronal death.
An intriguing clinical observation is that Alzheimer’s patients have significantly lower blood levels of 8 out of 10 studied antioxidants. This might suggest that oxidative stress plays a direct role in the pathogenesis of the disease. However, caution is warranted—this association could simply be a consequence of the illness, as individuals living with dementia often experience poor appetite and consume fewer fruits and vegetables.
This finding naturally prompted a key question: can antioxidant dementia supplements such as vitamin E, vitamin C, or beta-carotene provide neuroprotection and prevent Alzheimer’s? Decades of large-scale clinical trials have investigated this hypothesis, and the findings are unequivocal—and deeply disappointing.
Vitamin E and selenium: The PREADViSE trial
Can vitamin E act as a prevent dementia supplement?
Vitamin E is regarded as one of the most potent fat-soluble antioxidants and was long considered a promising candidate for reducing cognitive decline. The PREADViSE trial (Prevention of Alzheimer’s Disease by Vitamin E and Selenium) systematically investigated whether vitamin E or selenium could lower dementia incidence.
The result: vitamin E demonstrated NO efficacy in dementia prevention. Selenium, an essential trace element with antioxidant properties, was likewise completely ineffective. Participants who took vitamin E or selenium daily over several years developed dementia at the exact same rate as those in the placebo group.
This study was especially robust due to its long follow-up duration and large sample size. The hope that antioxidant dietary micronutrients could shield brain cells from neurodegeneration was not borne out by the data.
Why does vitamin E fail to provide neuroprotection?
Several mechanisms explain this lack of effect: first, oxidative stress in Alzheimer’s disease may be a downstream consequence rather than an underlying cause. Second, orally administered antioxidants may fail to cross the blood-brain barrier in sufficient concentrations. Third, Alzheimer’s is a complex condition driven by multiple pathological pathways that a single antioxidant cannot halt.
Beta-carotene and vitamin C: Long-term trials with mixed results
Beta-carotene: Does it affect men and women differently?
In the Harvard Physicians’ Health Study, nearly 6,000 older men were randomised to receive either beta-carotene or a placebo. Beta-carotene is a precursor to vitamin A found naturally in orange and yellow vegetables such as carrots and sweet potatoes.
After three years, no cognitive differences were observed between the groups. However, after 11 years, men taking the daily equivalent of beta-carotene found in roughly 150 grams of sweet potato showed modestly better cognitive performance. Whilst statistically significant, the clinical effect was very small.
Conversely, a comparable trial in older women found no cognitive benefit whatsoever after nine years. Why the discrepancy? It may take longer for any neuroprotective effect to manifest in women, or biological responses may differ by sex. Alternatively, the minor benefit seen in men may simply have been a statistical anomaly.
Vitamin C: Too little, too late?
Vitamin C, a water-soluble antioxidant, has also been evaluated in trials. In large-scale studies, vitamin C initially showed no measurable benefit—only at the nine-year assessment did the intervention group show a slight, questionable advantage.
When researchers evaluated combination therapies—vitamin C plus vitamin E and beta-carotene—two major trials (one with 1,500 participants over seven years, and another with over 20,000 participants over five years) found no cognitive benefit at all from antioxidant cocktails.
The conclusion is clear: antioxidant supplements, whether taken individually or combined, provide no reliable protection against Alzheimer’s disease or progressive memory impairment.
Multivitamin clinical trials: The Centrum Silver study
Are multivitamins the best vitamins for dementia patients?
If single vitamins fail to prevent cognitive decline, could a broad-spectrum multivitamin and multimineral formula help? The Harvard Physicians’ Health Study evaluated the daily use of Centrum Silver, one of the most widely used multivitamin preparations for older adults.
Over 12 years, thousands of men took either Centrum Silver or a placebo daily. The outcome was clear: the multivitamin group showed NO cognitive advantage over placebo. There was no improvement in memory, no slowing of cognitive ageing, and no reduction in dementia risk.
This trial carries substantial weight because multivitamins represent a significant portion of dementia supplements sold in the UK and globally. Many people take them hoping to protect their brain health, yet multivitamin clinical trials demonstrate that they offer no preventive benefit against Alzheimer’s disease.
What does this mean in clinical practice?
Multivitamins remain valuable for treating diagnosed nutritional deficiencies. However, for healthy individuals seeking to prevent Alzheimer’s, they are ineffective. Rather than spending money on unproven pills, resources are far better directed towards a nutrient-dense, wholefood diet rich in vegetables, fruit, and whole grains.
Souvenaid: The medical drink that fell short
Is Souvenaid the best supplement for Alzheimer’s patients?
Souvenaid is a medical nutrition drink formulated specifically for individuals diagnosed with Alzheimer’s disease. It features a patented nutrient blend known as Fortasyn Connect, containing omega-3 fatty acids, phospholipids, B vitamins, and other dietary micronutrients designed to support synapse formation and brain connectivity.
Despite heavy marketing and promising preclinical concepts, rigorous clinical trials have failed to confirm its efficacy.
Does Souvenaid slow cognitive decline?
Three large randomised controlled trials involving more than 1,000 participants evaluated the drink. The results were conclusively negative:
- Souvenaid did NOT prevent progression to dementia
- It produced little to no meaningful effect on memory impairment or broader cognitive function
- No significant therapeutic benefit was observed in patients with mild cognitive impairment (MCI) or established Alzheimer’s disease
A comprehensive 2020 Cochrane systematic review concluded that Souvenaid does not work. Despite biologically plausible mechanisms, the clinical outcomes failed to support its use.
This is particularly disappointing given the high cost of the product and its direct marketing to families affected by dementia. Current scientific evidence simply does not justify these claims.
Zinc and essential minerals: What supplements are best for dementia?
Can zinc supplementation improve cognitive impairment?
Zinc is an essential trace mineral required for hundreds of enzymatic processes, including synaptic transmission in the central nervous system. It was hypothesised that zinc supplements might improve cognitive performance in older individuals.
The ZENITH trial (Zinc Effects on Nutrient and Inflammatory Trends in Healthy ageing) tested this hypothesis systematically. The findings confirmed that zinc failed to improve global cognition across months and years of supplementation. Neither memory, attention, nor executive function showed measurable improvement.
As with vitamins, correcting a clinically confirmed zinc deficiency is important for general health, but zinc supplements offer no preventive efficacy against neurodegenerative disorders.
Calcium supplementation: Potential risks and adverse effects
Whilst most vitamins and minerals are merely ineffective, research into calcium supplementation has revealed concerning evidence of potential adverse effects on brain and cardiovascular health.
Can calcium supplements increase dementia risk?
Several clinical investigations suggest that calcium tablets may pose unexpected neurological hazards:
Cerebral white matter lesions: In a cross-sectional MRI study, older adults taking calcium supplements had significantly higher volumes of white matter hyperintensities. These lesions reflect microvascular ischaemic damage and mini-strokes, which are established risk factors for vascular dementia.
Doubled dementia risk: A longitudinal cohort study found that women using calcium supplements had a twofold higher risk of developing dementia. This risk was particularly pronounced in women with pre-existing cerebrovascular disease.
The Women’s Health Initiative: Uncovering cardiovascular and cognitive risks
The landmark Women’s Health Initiative trial randomised thousands of postmenopausal women to receive daily calcium plus vitamin D or a placebo over an eight-year period.
Initial analyses suggested no difference in dementia rates. However, a major methodological confounder was present: more than half of the enrolled participants were already taking over-the-counter calcium supplements prior to study entry, muddying the baseline comparisons.
When investigators re-analysed the data exclusively among women who were not previously taking calcium, a stark pattern emerged: calcium supplementation significantly increased the risk of myocardial infarction and stroke. A comprehensive meta-analysis confirmed a 15% increase in cardiovascular events among those taking calcium supplements compared to placebo.
Whilst specific re-evaluations of dementia incidence in this subgroup continue, the prevailing evidence indicates that routine calcium tablets may do more harm than good.
Should routine calcium supplementation be avoided?
For the majority of adults, the NHS recommends obtaining calcium directly through dietary sources—such as dairy products, fortified plant milks, dark green leafy vegetables, sesame seeds, and almonds. Routine supplementation should generally be reserved for individuals with specific medical indications under direct clinical supervision.
Why do dementia supplements fail in Alzheimer’s disease?
Given the vital physiological role of dietary micronutrients in brain function, why do dementia supplements consistently fail in clinical trials?
Several key factors account for this failure:
- Multifactorial pathology: Alzheimer’s disease involves intricate cascades—amyloid-beta deposition, neurofibrillary tangles, neuroinflammation, and vascular dysfunction. An isolated micronutrient cannot alter these complex pathological processes.
- Timing of intervention: Neuropathological changes develop decades before noticeable memory impairment occurs. Administering supplements once clinical symptoms emerge is likely too late to halt neurodegeneration.
- Bioavailability and transport: High oral doses of vitamins may not achieve therapeutic concentrations within the brain parenchyma or across the blood-brain barrier.
- Nutrient synergy vs isolation: Whole foods contain hundreds of bioactive compounds that work synergistically. A single synthetic vitamin cannot replicate the matrix effects of a balanced diet.
- Absence of baseline deficiency: Most participants in clinical trials already possess adequate baseline nutritional status. In well-nourished populations, surplus micronutrients offer no additional neuroprotection.
What Really Works Against Alzheimer’s Disease: Beyond Dementia Supplements
If dementia supplements do not work, what does? The good news is that there are genuinely effective measures for reducing your risk of Alzheimer’s disease, firmly rooted in robust scientific evidence.
Diet: Whole Foods Instead of Dietary Micronutrients in Pills
Rather than swallowing isolated vitamins or wondering what supplements are best for dementia, focus on a wholesome, plant-based diet to support long-term neuroprotection:
- Plenty of colourful fruit and vegetables (for proven antioxidant efficacy)
- Wholemeal products and whole grains
- Nuts and seeds
- Pulses and legumes
- Omega-3-rich foods (linseeds, walnuts, oily fish)
Both the Mediterranean diet and the MIND diet have shown in clinical trials that they can lower the risk of cognitive decline and Alzheimer’s disease.
Physical Activity: An Underrated Protective Factor
Regular physical exercise is one of the most powerful defences against neurodegeneration. Just 30 minutes of brisk walking per day can significantly cut your risk and help stave off memory impairment.
Mental Stimulation and Social Connections
An active brain undergoes slower ageing. Reading, solving puzzles, learning new skills, or playing a musical instrument all help maintain cognitive reserve. Equally vital is maintaining meaningful social connections and an active social life.
Managing Cardiovascular Risk Factors
High blood pressure, diabetes, obesity, and smoking substantially increase your risk of Alzheimer’s disease. Controlling these health factors is far more critical than purchasing any dementia supplements UK health shops sell.
Sleep and Stress Management
Getting sufficient, good-quality sleep is indispensable for brain health. During deep sleep, the brain clears out toxic proteins associated with neurodegeneration. Chronic stress also harms delicate neural circuits—relaxation techniques like mindfulness and meditation can provide valuable neuroprotection.
Conclusion: Why You Should Steer Clear of Ineffective Dementia Supplements
The clinical evidence is clear: vitamin and mineral products are unlikely to prevent or treat Alzheimer’s disease. Findings across major multivitamin clinical trials confirm this lack of benefit for vitamin E, vitamin C, beta-carotene, everyday multivitamins like Centrum Silver, specialised medical drinks such as Souvenaid, zinc, and numerous other preparations.
Particularly concerning are the documented adverse effects: routine calcium supplementation may actually elevate dementia risk and has been linked to a higher incidence of heart attacks and strokes.
The multi-billion-pound supplement industry thrives on unsubstantiated hope, promising mental sharpness and protection against cognitive decline. The clinical reality is sobering: 14 major scientific studies involving tens of thousands of participants show that these products fail to deliver on their promises.
Save your money and invest in proven lifestyle interventions instead: a nutrient-rich wholemeal diet, regular exercise, intellectual and social engagement, restorative sleep, and proactive stress management. These are the true protective factors against Alzheimer’s disease—and they will not cost you an extra penny, just a little personal commitment.
Scientific References
- Mullan K, Cardwell CR, McGuinness B, Woodside JV, McKay GJ. Plasma antioxidant status in patients with alzheimer’s disease and cognitively intact elderly: a meta-analysis of case-control studies. J Alzheimers Dis. 2018;62(1):305-317.
- Kryscio RJ, Abner EL, Caban-Holt A, et al. Association of antioxidant supplement use and dementia in the Prevention of Alzheimer’s Disease by Vitamin E and Selenium trial (PREADViSE). JAMA Neurol. 2017;74(5):567-573.
- Grodstein F, Kang JH, Glynn RJ, Cook NR, Gaziano JM. A randomized trial of beta carotene supplementation and cognitive function in men: the Physicians’ Health Study II. Arch Intern Med. 2007;167(20):2184-2190.
- Kang JH, Cook NR, Manson JE, Buring JE, Albert CM, Grodstein F. Vitamin E, vitamin C, beta carotene, and cognitive function among women with or at risk of cardiovascular disease: The Women’s Antioxidant and Cardiovascular Study. Circulation. 2009;119(21):2772-2780.
- Yaffe K, Clemons TE, McBee WL, Lindblad AS, Age-Related Eye Disease Study Research Group. Impact of antioxidants, zinc, and copper on cognition in the elderly: a randomized, controlled trial. Neurology. 2004;63(9):1705-1707.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):23-33.
- Burckhardt M, Watzke S, Wienke A, Langer G, Fink A. Souvenaid for Alzheimer’s disease. Cochrane Database Syst Rev. 2020;12(12):CD011679.
- Maylor EA, Simpson EEA, Secker DL, et al. Effects of zinc supplementation on cognitive function in healthy middle-aged and older adults: the ZENITH study. Br J Nutr. 2006;96(4):752-760.
- Payne ME, McQuoid DR, Steffens DC, Anderson JJB. Elevated brain lesion volumes in older adults who use calcium supplements: a cross-sectional clinical observational study. Br J Nutr. 2014;112(2):220-227.
- Kern J, Kern S, Blennow K, et al. Calcium supplementation and risk of dementia in women with cerebrovascular disease. Neurology. 2016;87(16):1674-1680.
- Rossom RC, Espeland MA, Manson JE, et al. Calcium and vitamin D supplementation and cognitive impairment in the women’s health initiative. J Am Geriatr Soc. 2012;60(12):2197-2205.
- Hsia J, Heiss G, Ren H, et al. Calcium/vitamin D supplementation and cardiovascular events. Circulation. 2007;115(7):846-854.
- Grodstein F, O’Brien J, Kang JH, et al. Long-term multivitamin supplementation and cognitive function in men: a randomized trial. Ann Intern Med. 2013;159(12):806-814.
- Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women’s Health Initiative limited access dataset and meta-analysis. BMJ. 2011;342:d2040.



